Simulations Plus, Inc. (SLP)
Nasdaq · Healthcare · Health Information Services
$18.500.00%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $374M
- P/E (trailing)
- 46.3
- Forward P/E
- 21.0
- 52-week range
- $11.09 – $21.01
- 52-week change
- +11.78%
- EPS (trailing)
- $0.40
- Next earnings
- Oct 29, 2026
Fiscal year to Aug 2025
- Revenue
- $79.2M (+13.09%)
- Net income
- −$64.7M
- Operating margin
- −89.3%
- Diluted EPS
- −$3.22
- Free cash flow
- $17.4M
From the company’s annual report on SEC EDGAR.
About Simulations Plus, Inc.
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through Software and Services segments. The company offers GastroPlus, which predicts absorption, biopharmaceutics, pharmacokinetics, and pharmacodynamics in humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, OBESITYsym, and Thales products. In addition, the company offers Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions.
Headquarters: Research Triangle Park, United States · 212 employees · simulations-plus.com